Rob Dillard

DocwireNews

The prevalence of Bruton&rsquo;s tyrosine kinase (BTK) C481 mutations, a known cause of resistance to BTK inhibitors (BTKi), might be higher in chronic lymphocytic leukemia (CLL) patients with longer BTKi exposure, according to a study <a href="https://ash.confex.com/ash/2023/webprogram/Paper181105.html" target="_blank" rel="noopener">presented</a> at the 65th ASH Annual Meeting &amp; Exposition, which is taking place December 9-12 in San Diego, California.&ldquo;Almost two-thirds of [patients] whose disease progresses on a covalent BTKi have a BTK C481 mutation detectable at progression. Furthermore, BTK C481 mutations have been detected up to 28 months before progression among [patients] with CLL/[small lymphocytic lymphoma (SLL)] treated with a covalent BTKi. The early identification of patients who are at risk for developing covalent BTKi resistance is critical to optimize clinical treatment of [patients] with CLL/SLL,&rdquo; the researchers wrote.In this cross-sectional study, Jennifer Prescott and colleagues assessed the prevalence of BTK C481 mutations in 130 patients with CLL/SLL. The researchers noted that DNA was assayed from blood samples collated for 6 BTK C481 mutations known to confer resistance to covalent BTKi (c.1442G&gt;C, c.1441T&gt;A, c.1442_1443delinsCT, c.1442G&gt;T, c.1441T&gt;C, and c.1442G&gt;A). Patients were considered to have a BTK C481 mutation if any of the 6 variants showed an abnormal limit of detection.&ldquo;Because two-thirds of BTKi-experienced [patients] had &lt;36 [months] of BTKi exposure, the prevalence of BTK C481 mutations may be higher in populations with longer BTKi exposure,&rdquo; the researchers concluded. &ldquo;Further analyses of the natural history of BTK C481 mutations will help identify patients who are at risk of covalent BTKi resistance.&rdquo;ReferencePrescott J, Steiniche T, Georgsen J, et al. Prevalence of resistance-associated Bruton tyrosine kinase (BTK) C481 mutations by prior treatment status among patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): a real-world observational study. Abstract #4196. Presented at the 65th ASH Annual Meeting &amp; Exposition; December 9-12, 2023; San Diego, California.

Kaitlyn Kosko

Pembrolizumab Plus Trastuzumab/Pertuzumab Shows Promise in HER2-Positive Breast Cancer

HER2 Breast Cancer

MarkAlain Déry, DO, MPH, FACOI

Autism Rates Reach New High in U.S. Children: Here’s What It Really Means

Neurodivergent

Jordana Jampel

Annual US Measles Cases Top 1,000, Worst Year Since Elimination

Infectious Disease

Latest News

BTK C481 Mutations Higher Among CLL Patients With Longer BTKi Exposure

Conference Coverage

The prevalence of BTK C481 mutations, a known cause of resistance to BTK inhibitors, might be higher in CLL patients with longer exposure to BTKi.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe